PNC-27 vs FOXO4-DRI
Cancer-membrane-targeting peptide vs senolytic peptide.
| Attribute | PNC-27 p53-derived anticancer peptide | FOXO4-DRI Senolytic peptide |
|---|---|---|
| Category | Experimental Research Compounds | Longevity & Healthy Aging |
| Best known for | Cancer-cell-selective membrane-disrupting peptide research | Senolytic / senescent-cell clearance research |
| In plain English | An experimental peptide designed in cancer research labs to selectively damage cancer cell membranes while sparing healthy cells. | It blocks a 'don't die' signal in senescent cells so they undergo apoptosis instead of lingering. |
| How it works | Binds HDM-2 on cancer cell membranes and forms transmembrane pores leading to necrosis, with minimal effect on cells lacking surface HDM-2. | Disrupts the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis selectively in senescent (not healthy) cells. |
| Researchers study | Pancreatic, leukemia, and solid tumor cell lines in vitro and in animal models. | Aged mice, fibrosis, frailty, and chemotherapy-induced senescence. |
| Internet discussion | Discussed in alternative cancer research circles; controversial and not clinically approved. | One of the most-hyped longevity peptides on biohacker forums. |
PNC-27
Cancer-cell-selective membrane-disrupting peptide research
An experimental peptide designed in cancer research labs to selectively damage cancer cell membranes while sparing healthy cells.
Binds HDM-2 on cancer cell membranes and forms transmembrane pores leading to necrosis, with minimal effect on cells lacking surface HDM-2.
Pancreatic, leukemia, and solid tumor cell lines in vitro and in animal models.
Discussed in alternative cancer research circles; controversial and not clinically approved.
PNC-27 is an experimental anticancer research peptide that disrupts cancer cell membranes by binding membrane HDM-2, studied strictly in preclinical models.
FOXO4-DRI
Senolytic / senescent-cell clearance research
It blocks a 'don't die' signal in senescent cells so they undergo apoptosis instead of lingering.
Disrupts the FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis selectively in senescent (not healthy) cells.
Aged mice, fibrosis, frailty, and chemotherapy-induced senescence.
One of the most-hyped longevity peptides on biohacker forums.
FOXO4-DRI is a designed senolytic peptide researched for selective clearance of senescent cells.